The randomised MUST trial suggests no additional benefit on joint signs and symptoms from adding or continuing methotrexate therapy.

Takeaway

• Ustekinumab monotherapy was noninferior to ustekinumab and methotrexate combination therapy for reducing disease activity in the joints of patients with active psoriatic arthritis.

Why this matters

• Evidence on the effect...